Nova Eye Medical (Nova Eye Medical) 3-Year EBITDA Growth Rate : -16.10% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Nova Eye Medical 3-Year EBITDA Growth Rate?

Nova Eye Medical's EBITDA per Share for the six months ended in Dec. 2023 was $-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was -16.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -23.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nova Eye Medical was 75.00% per year. The lowest was -49.00% per year. And the median was 8.90% per year.

Competitive Comparison of Nova Eye Medical's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Nova Eye Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nova Eye Medical's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nova Eye Medical's 3-Year EBITDA Growth Rate falls into.

Nova Eye Medical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Nova Eye Medical (OTCPK:ELXMF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Nova Eye Medical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Nova Eye Medical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nova Eye Medical (Nova Eye Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nova Eye Medical Ltd (OTCPK:ELXMF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

EYE:Australia

Address

107 Rundle Street, Kent Town, Adelaide, SA, AUS, 5067

Website

https://www.nova-eye.com

Nova Eye Medical Ltd is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of revenue from the United States of America.

Nova Eye Medical (Nova Eye Medical) Headlines

From GuruFocus

ABK Biomedical Appoints Michael J. Mangano as President and Chief Executive Officer

By PRNewswire PRNewswire • 07-30-2018

Nova Eye Medical Announces U.S. Market Clearance of the iTrack� Advance Canaloplasty Device

By Business Wire Business Wire • 04-12-2023